Onisiforou, A., Charalambous, E
Semaglutide activates GLP-1 receptors in your brain and gut, triggering appetite suppression and improved blood sugar controlbut weight loss speed varies significantly between individuals
July 11th, 2025: Ozempic Vision Loss Lawsuit Filed After 85% Eye Damage Alleged from NAION On July 10, 2025, a new lawsuit was filed in the Southern District of New York alleging that Ozempic caused 85% vision loss in one eye due to non-arteritic anterior ischemic optic neuropathy (NAION)
Gastrointestinal side effects remain a concern
The June 23 report said the request came from someone well connected, but STAT could not determine the patients identity
Widespread physician awareness, favorable reimbursement policies, and significant investments from leading pharmaceutical companies have driven strong uptake of GLP-1 treatments